|
1 Indications And Usage Trikafta Is Indicated For The Treatment Of Cystic Fibrosis (Cf) In Patients Aged 12 Years And Older Who Have At Least One F508del Mutation In The Cystic Fibrosis Transmembrane Conductance Regulator (Cftr) Gene. If The Patient's Genotype Is Unknown, An Fda-Cleared Cf Mutation Test Should Be Used To Confirm The Presence Of At Least One F508del Mutation. Trikafta Is A Combination Of Ivacaftor, A Cftr Potentiator, Tezacaftor, And Elexacaftor Indicated For The Treatment Of Cystic Fibrosis (Cf) In Patients Aged 12 Years And Older Who Have At Least One F508del Mutation In The Cftr Gene. If The Patient's Genotype Is Unknown, An Fda-Cleared Cf Mutation Test Should Be Used To Confirm The Presence Of At Least One F508del Mutation. ( 1 )
|